Vice President, Global Solutions
Industry Vertical Leader, Life Sciences
Kelly Services, Inc.
In this episode, Kevin D. Duffy discusses sourcing talent in the life science industry, strategic partnering for acquiring talent, the concept of talent supply chain management, and a glimpse into the future.
Head of Global Brand & Customer Experience
In this episode, Mark Sales discusses pharma brand marketing, product marketing, B2B vs. B2C, and how pharma marketers can make improvements in traditional areas of weakness. You can also download a related white paper on pharma brand marketing.
SVP, Behavioral Strategy
Adheris Health, Behavioral Insights Group of inVentiv Health
In this episode, you’ll hear a conversation with Dr. Kathleen Starr, a psychologist and leader of a team of behavioral scientists at inVentiv Health. Kathleen is interviewed by Sydney Rubin, a senior communications consultant with inVentiv Health. You are also encouraged to … Read More »
In this episode, Mr. Fronstin illustrates the size and scope of the pain market, addresses current unmet needs, outlines promising new Mechanisms of Action, and covers the implications for the pharma industry.
In this episode, Mr. Patel talks about data security, US legislation, including the Affordable Care Act, safeguards that can be implemented, and other challenges regarding data security. Download the related whitepaper entitled 'Global Digital Security: The Human Elemen … Read More »
In this episode, Mr. McCormick talks about outsourced contact centers serving the healthcare industry and focuses on TrialCard's customer experience center. Download the related whitepaper entitled 'What Would Alexander Graham Bell Think Of Today's Contact Cen … Read More »
In this episode, Mr. Domann discusses a retail strategy for minimizing prescription abandonment for brands at many stages in the product lifecycle. We cover how pharmacies and pharmacists play integral roles in the strategy.
In this episode, Patricia Ensor discusses the characteristics and behaviors of the uninsured, how they relate to the Affordable Care Act (ACA), and what it means for Pharma.
In this episode, Ms. Ruby discusses how clinical trials are like skydiving, what some of the key challenges are in clinical trials, solving unexpected challenges, and creating a productive and collaborative relationship between CROs and sponsors.
In this episode, Mr. Penniston and Ms. Taber talk about risk-based monitoring what it is, why it's important, what are the components, what skill sets or tools are necessary, and the challenges and opportunities related to risk-based monitoring.
The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biobetters are the next big opportunity for biopharma to benefit from this growth. This podcast will explore the regulatory and scientific considerations for the development of biobetters.
In this episode, Mr. Lammers talks about using a multichannel business strategy in life science companies. He defines the multichannel approach, covers the core challenges, offers his review on Pharma's adoption of multichannel, and provides advice for commercial leader … Read More »
In this episode, we discuss the challenges in pharma regarding workforce management, the growing trend of strategic workforce planning, and how this phenomenon will continue to evolve over the next 5 years.
In this episode, Mr. Dockery covers several issues related to patient adherence, including using Big Data to predict patient behavior and improve adherence in a patient population, as well as how to accurately measure adherence rates.
In this episode, Craig Flanagan and DJ Mitsch talk about a major culture change at Sanofi Pharmaceuticals North America: how they designed it, implemented it, what the results were, and the future of this significant undertaking. This podcast will be of great interest to any … Read More »
In this episode, Ms. Harrison discusses the past, present, and future of Risk-based Monitoring. She also covers challenges and solutions, as well as a real-life example of RBM in a clinical study.
In this episode, Dr. Davis discusses open innovation, nontraditional partnerships, collaboration, new technologies, and the future of R … Read More »
In this episode, Mr. O'Grady speaks about immersive learning, what it is, and how it is the best choice for many types of mission-critical training.
In this episode, Peter Wunderli, Ph.D., discusses PPD's recent laboratory facility expansion, outlines challenges and critical factors in cell-based bio bioassay product development, talks about disease states suitable for this type of technology, and finally, takes a l … Read More »
In this episode, Anthony Rotolo talks about creativity in the health and wellness space. We cover the importance of creativity in advertising, how to be creative, and, when used properly, how creativity influences behavior change.
In this episode, Stacy Simpson Logan talks about the value of obtaining a CMPP credential for employees and employers as well as the future of the CMPP program. CMPP stands for Certified Medical Publication Professional and is administered by ISMPP, the International Society … Read More »
This podcast describes how Managed Access Programs can continue treatment access for patients coming out of registration or other clinical trials who need to transition to commercial supply.
In this episode, Ms. Hammond talks about our aging society and how the industry needs to address its therapies to reflect the differences in age groups, including the old, and the very old.
In this episode, we discuss how user testing research improves the clinical trial process for patients, sites, and sponsors.
In this episode, we discuss standard of care in clinical trials, challenges for sites and sponsors, and how standard of care issues affect day-to-day work in trials.
In this episode, Mr. Lewis discusses how pharma can better connect with HCP audiences using authentication, list matching, and other techniques. He also covers how effective communications can impact prescription writing, and how to overcome hurdles from Medical, Legal, and … Read More »
In this episode, our experts discuss the primary challenges regarding women's health in clinical research. They also cover pregnancy registries and lactation studies, as well as available regulatory guidance related to this type of research.
In this episode, Professor Wischik describes his ongoing journey of research and development for Alzheimer's Disease. This intriguing podcast covers the man, the molecule, and the market.
In this episode, Dr. Slonim discusses ACOs, how they offer a new model for health care, how they create opportunities for biopharmaceutical companies, and how a shift to ACOs would affect all facets of the health care continuum.
In this episode, Mr. Nugent discusses the challenges of using email in pharmaceutical marketing, as well as some best practices for achieving the highest possible ROI.
In this episode, our experts discuss pharmacy-based patient recruitment programs for clinical trials.
In this episode, Rodeina Challand clears up some of the murkiness among the many terms associated with biosimilars. Then, we cover the legislation and guidelines affecting biosimilars, we discuss the possibilities of one global program, and finally talk about the future for … Read More »
In this episode, Mr. Lapsker discusses how adaptability is necessary to remaining a viable and successful business in an era of regulatory change. He also explains how all forms of marketing to HCPs are not equal.
In this episode, our panel discusses pharmacovigilance as it relates to organizational transformation. The podcast covers collaboration, capacity management, globalization, information and analytics, and transparency and trust.
In this episode, Mr. Shapiro discusses why patient support programs are valuable, how to start a program, the necessity for delivering personalized information, several critical success factors for a program, and understanding health care from the patient's perspective.
In this episode, Dr. Isherwood shares some insightful research on the Russian people, including their health behaviors and attitudes, as well as the state of the health care system in Russia.
In this episode, Taren Grom, Editor-in-Chief of PharmaVOICE, leads a discussion that focuses on a recent study on women's views and practices regarding health and health decisions for their families. The study uncovered seven lenses for marketing health to women. You … Read More »
In this episode, Mr. Connor shares 4 of his top 10 myths about patient enrollment and retention, and we'll tell you where to get the entire list.
In this episode, Mr. Estcourt shares his perspective on programs that enable patient access to medicines outside the clinical trial or commercial setting and the barriers that remain despite well-defined regulations governing such access.
In this episode, Mr. Shapiro describes his experiences working with companies on successful tele-detailing and tele-sales programs, including numerous insights on the unforeseen benefits of these solutions.
In this episode of the PharmaVOICE Executive Suite Podcast Series, Mr. Lipset, shares his thoughts on being Chairman of the 2012 DIA Annual Meeting in June, and how his work at Pfizer helps him in his role with DIA including this year's theme on collaboration. He also c … Read More »
In this episode, Dr. Dunsire shares her insights on the quest to find a cure for cancer, on women striving for positions in the C-Suite, and thoughts on her own career development and recognition as the 2009 HBA Woman of the Year.
In this episode, Dr. Malcolm discusses how the role of the CRO is transitioning from commodity service supplier to strategic partner, and the unintended negative consequences this could have on what is already the most expensive part of clinical trials: patient enrollment.
In this episode, a trio of experts from Cognizant talk about numerous issues involving social media in the life sciences. There is also a related white paper you may download.
In this episode, Dr. Lobel talks about Drug-induced liver injury, also known as DILI. Weâll cover what DILI is, how it is identified, and its effects on the clinical development process. At the end of this podcast, youâll learn where you can download a related white pape … Read More »
In this episode, Dr. Thompson talks about how biotech is making improvements in the standard of care, and the impact of Pharma 3.0. He also talks about his own experience taking REOLYSINÂ® through the drug development process, the genesis of Oncolytics Biotech, and shares so … Read More »
In this episode, Mr. Shecterle discusses FCPA Compliance and anti-bribery practices at large pharmaceutical and life sciences companies.
In this episode, Mr. Shapiro talks about the challenges life science companies face when providing information on their products to physicians and healthcare providers.
In this episode, Mr. DeAngelis discusses a variety of issues regarding consumers' usage of social media for healthcare information. You'll learn some of the results of a study of over 1,400 U.S. consumers participating in proprietary panels and web communities.
In this episode, Mr. Smith talks about clinical trial enrollment and the concept of Additive Patient Recruitment.
In this episode, Mr. Pomerantz talks about the influence of patients in pharma and especially in emerging markets such as Brazil.
In this episode Ms. Larrabee discusses clinical trials in emerging countries, and the major planning challenges, plus how collaborative partnerships are helping in the search for new treatments. For more information about ClearTrial, visit www.cleartrial.com.
In this episode, Mr. Shapiro shares his views on how pharmaceutical, biotech, and medical device companies can benefit from partnering with a qualified pharmaceutical call center. For more information about PhoneScreen, visit www.phonescreen.com.
In this episode, the team at Roska Healthcare discusses new ways to use behavioral and attitudinal data to enhance customer targeting and messaging. They review a unique, new communications model (Catalyst-tm) that increases customer 'acceptance' (engagement) and d … Read More »
In this episode, Ms. Cooke discusses what it means to be honored as Mentor of the Year, why mentoring is an important career development strategy, and the HBA's commitment to helping its members develop their careers through mentoring and coaching.
In this episode, Mr. Bartolacci discusses Key Opinion Leaders and Influence Mapping studies.
In this episode, Mr. Dietlin discusses a burgeoning concept called the Networked Drug Development Alliance, what it is, what's driving it, and how they improve the process for pharmaceutical companies and investors.
In this episode, Mr. Yoder talks about how optimizing is not the same as cost reduction. He also covers the challenges, benefits, and what the future of clinical supply optimization looks like.
In this episode, Mr. Hunter, discusses the many variables and issues surrounding transportation and distribution of product for global clinical trials.
In this episode, Mr. Scarbath discusses the movement into voice biometrics for voice signatures and authentication. He provides a general overview of the technology and how it is being applied in the pharmaceutical industry and sampling world.
In this episode, Ed Watson discusses some of the challenges associated with recruiting for clinical studies in oncology, the roles of various key stakeholders, and the sponsor community's response to a new approach to patient accrual.
In this episode, Mr. Shea, discusses how clinical trials are affected by label text issues, streamlining the process with a phrase library, and the advantages of managing a phrase library with a dedicated system.
In this episode, our thought leaders discuss what ISMPP is and how it's evolved, how the organization can help Medical Publication Professionals, and the 2011 annual meetings in the US in April and in Europe in November.
In this episode, Dr. Bannon and Dr. Brennan discuss conducting clinical trials in India. They cover why a seamless communication strategy is important, how an in-country partner can improve the trial outcome, regulatory issues in India, and the ROI of conducting clinical tri … Read More »
In this episode, Pali F. Kollath discusses Central and Eastern Europe as an emerging market for pharmaceutical companies. You'll learn how large this market is, the benefits of moving into this market, some of the risks and challenges, best practices for setting up opera … Read More »
In this episode, Mr. DeSanti discusses Integrated Solutions in clinical research. We define the concept, outline which sponsors can utilize it, and finally, we cover the benefits and ROI of an integrated approach.
In this episode, Katie Mihelich and Danielle Jamil provide a redefinition of CRM, and focus in on how it can be used in the rare disorder market space. They'll provide some best practices and key learnings about communicating with the stakeholders in the rare disorder co … Read More »
In this episode, Mr. Terry shares his perspective on how drug developers can move beyond the typical, transactional, approach to outsourcing and instead, create true partnerships with their CROs that reflect a commitment to a shared development vision.
In this episode, Srivatsan and Dr. Nash discuss a forward-thinking business model that focuses on overall patient wellness and preventative medicine rather than simply treating illness.
In this episode, Dr. Wagner talks about China as an emerging market for cancer drugs, including the differences between the U.S. and China in terms of access to testing and drugs, as well as differences in healthcare coverage. We'll also discuss some of Kantar's late … Read More »
In this episode, Mr. DeSanti discusses remote source document verification, also known as rSDV. First we’ll define rSDV, and then talk about the benefits, challenges, and the ROI of implementing rSDV, as well as other issues.
In this episode, Mr. DeSanti discusses the clinical trials trend of moving to an Electronic Trial Master File platform. He covers the strategic and practical aspects of making the move, and what the payback is for doing so.
In this episode, we'll discuss using comparator dugs in clinical trials, and overcoming the issues and challenges of using comparators.
In this episode, we'll discuss AstraZeneca's recent move to the cloud. The company switched from an on-premise, custom-developed CRM system to Veeva Systems' multi-tenant SaaS CRM system.
In this episode, our thought leaders discuss ways for CROs and sites to work together to achieve the best possible results. This episode is chock full of best practices and tips, as well as an overview of the results of a July 2010 survey of sites.
In this episode, Mr. Wallach discusses how pharmaceutical companies can benefit from Software as a Service and Cloud Computing to improve the sales process within the life-sciences industry.
In this episode, we have three distinguished speakers. First, we have Nagaraja Srivatsan, Vice President, Head of Life Sciences, North America at Cognizant. We also have Ramana Reddy, Practice Leader – Life Sciences at Cognizant Business Consulting and finally, Krishnan Raja … Read More »
In this episode, Mr. Smith provides detailed information related to security standards in patient recruitment, what clinical teams need to consider when selecting the right recruitment partner, and how to navigate and understand the complex guidelines and regulations in this … Read More »
In this episode Mr. Dietlin talks about Clinical Delivery Alliances; what they are and how they can benefit the drug development process.
In this episode we'll cover various topics pertaining to marketing research in the pharmaceutical industry. We have three distinguished thought leaders who represent different perspectives on marketing research, and offer some takeways from the 2010 PMRG Annual Conferen … Read More »
In this episode, Ms. Wisener describes how expanded access and named-patient programs can help successfully meet patients' needs while addressing the unique challenges faced by smaller and emerging companies.
In this episode, Ms. Fischer and Mr. Rooke discuss best practices for brand stewardship and how to maintain creative integrity. They cover the issues as they relate to the client, the consumer, and the agency.
In this episode, Mr. Connor describes how social networking can be used as a powerful business tool for patient recruitment for clinical trials.
In this episode, Mr. Fox discusses incentive compensation plans in the pharmaceutical industry, why the incumbent plans aren't working, and how new solutions have emerged that improve the accuracy and efficiency of plans.
In this episode we cover the Medical Publishing Insights and Practices (MPIP) initiative, a relatively new development co-sponsored by Amgen, AstraZeneca, GlaxoSmithKline, Pfizer and the International Society for Medical Publication Professionals (ISMPP). Ms. Mansi and Dr. G … Read More »
Mr. Holstein and Mr. Michaelson discuss the benefits and challenges of the new agency model that has emerged with the growth of digitally enabled communications.
Dr. Malcolm talks about risk sharing and performance-based pricing as a way for sponsors to get the best results for their patient recruiting budget.
Ms. Brescia provides an overview of the e-patient, how this special patient population can be leveraged for clinical trial participation, and how social media are impacting recruitment and clinical research.
Dr. Malcolm talks about planning and measuring return on investment in patient recruitment today, as well as what the future holds in this area.
In this special PharmaVOICE 100 podcast, Ms. Cooke outlines the current state of women in healthcare, discusses the importance of mentoring, and shares her views on volunteerism. This episode also provides an overview of the HBA and its upcoming Annual Leadership Conference … Read More »
In this special PharmaVOICE 100 podcast, Mr. Tramuto discusses digital technologies that educate and provide important services to healthcare providers to improve communication and help deliver better patient outcomes.
In this special PharmaVOICE 100 podcast, our thought leaders discuss the current state of the life-sciences industry, the changes it is experiencing now, and what the industry will look like in the next decade.
Dr. Reiter discusses why it's important to maintain R&D spending during fiscally challenging times, the pros and cons of a global R&D plan, how to do more with less, what technology brings to the table, and other critical factors to improve the development process.
In this episode, Dr. Ball and Mr. LeVine discuss the importance of patient feedback Â how to obtain it and how it can be used to better connect brands with patients and physicians in a practice setting.
In this episode, Mr. Bain and Mr. Iberson-Hurst discuss CDISC's efforts in instituting standards for Electronic Health Records and RFD – Retrieve Form for Data Capture. They also cover where the organization's efforts will be applied in the future.
In episode three, of a three-part series, “Surviving to Thriving in Stormy Weather,” our thought leaders discuss declining R & D productivity combined with increasing development costs. They offer insights and solutions to maximizing efficiencies and effecting ch … Read More »
In episode two, of a three-part series, “Surviving to Thriving in Stormy Weather, ” our thought leaders discuss new commercialization processes as healthcare moves towards personalized medicine. They also cover how to assess market potential for personalized therapies, post- … Read More »
In this episode, Mr. Dearhammer and Ms. Goss discuss the need for metrics and standards for clinical trials management and the impact of the Metrics Champion Consortium (MCC) on CROs and sponsors.
In episode one, of a three-part series, “Surviving to Thriving in Stormy Weather,” Mr. Hagan and Mr. Kirk discuss market pressures and how economic turmoil in the biopharma industry can be overcome by using process optimization.